Bank of New York Mellon Corp Buys 37,317 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Bank of New York Mellon Corp boosted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXFree Report) by 6.3% during the 3rd quarter, HoldingsChannel reports. The fund owned 634,010 shares of the company’s stock after purchasing an additional 37,317 shares during the period. Bank of New York Mellon Corp’s holdings in Recursion Pharmaceuticals were worth $4,850,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Baldwin Brothers LLC MA increased its stake in Recursion Pharmaceuticals by 33.3% during the third quarter. Baldwin Brothers LLC MA now owns 7,336 shares of the company’s stock worth $56,000 after acquiring an additional 1,834 shares during the last quarter. Amundi boosted its position in shares of Recursion Pharmaceuticals by 69.6% during the fourth quarter. Amundi now owns 7,189 shares of the company’s stock valued at $57,000 after buying an additional 2,949 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Recursion Pharmaceuticals by 453.7% during the second quarter. Allspring Global Investments Holdings LLC now owns 8,073 shares of the company’s stock valued at $60,000 after buying an additional 6,615 shares during the period. Accel Wealth Management boosted its position in shares of Recursion Pharmaceuticals by 69.3% during the second quarter. Accel Wealth Management now owns 10,330 shares of the company’s stock valued at $77,000 after buying an additional 4,230 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its position in shares of Recursion Pharmaceuticals by 11.1% during the second quarter. Ameritas Investment Partners Inc. now owns 11,270 shares of the company’s stock valued at $84,000 after buying an additional 1,129 shares during the period. 57.82% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on RXRX shares. JPMorgan Chase & Co. dropped their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set a “neutral” rating for the company in a research report on Monday, November 13th. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, January 16th. Finally, TD Cowen began coverage on Recursion Pharmaceuticals in a report on Friday, January 26th. They issued a “market perform” rating for the company.

Read Our Latest Analysis on RXRX

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ RXRX opened at $9.41 on Thursday. The firm has a market capitalization of $2.04 billion, a price-to-earnings ratio of -6.45 and a beta of 0.63. The stock has a 50 day moving average price of $9.52 and a 200 day moving average price of $8.89. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.54 and a 52-week high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Free Report) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The firm had revenue of $10.53 million during the quarter, compared to analysts’ expectations of $12.20 million. Recursion Pharmaceuticals had a negative net margin of 617.74% and a negative return on equity of 64.20%. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.68 earnings per share for the current year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, COO Tina Marriott Larson sold 8,000 shares of the company’s stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $10.35, for a total transaction of $82,800.00. Following the completion of the sale, the chief operating officer now owns 414,548 shares in the company, valued at $4,290,571.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Recursion Pharmaceuticals news, insider Shafique Virani sold 18,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $6.51, for a total transaction of $117,180.00. Following the completion of the sale, the insider now owns 140,351 shares in the company, valued at $913,685.01. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Tina Marriott Larson sold 8,000 shares of the company’s stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $10.35, for a total value of $82,800.00. Following the transaction, the chief operating officer now directly owns 414,548 shares in the company, valued at $4,290,571.80. The disclosure for this sale can be found here. Insiders sold a total of 351,710 shares of company stock worth $3,155,253 over the last 90 days. Company insiders own 19.96% of the company’s stock.

Recursion Pharmaceuticals Profile

(Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers.

Read More

Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXFree Report).

Institutional Ownership by Quarter for Recursion Pharmaceuticals (NASDAQ:RXRX)

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.